Phosphorex Appoints Jerry Williamson as Chief Executive Officer

HOPKINTON, Mass., Sept. 19, 2022 /PRNewswire/ — Followi capital investment from Ampersand Capital Partners, Phosphorex, a drug contract developm e nt and manufacturing organization (“CDMO”) providin polymer / lipid nanoparticles , announced today the appointment of Jarl Executive Officer.

Jarlath has over 25 years of experience in the biopharmaceutical ind management positions within various contract research and contract m organizations. M ost recently, Jarlath served as the President and CE Laboratories, a CDMO focused on ge ne therapy viral vectors and oncolyti Prior to Advanced Bioscience Laboratories, Jarlat h held various sen MilliporeSigma, leading the global BioReliance® commercial operations function. Jarlath also held commercial and technical roles at industry leading organiz GE and Lonza Bio logics.

Bin Wu, Ph.D., Founder of Phosphorex, will assume the newly created role of President and Chief Scientific Officer. Bin
commented, “Jarlath is a highly accomplished leader of customer-focused, science-driven organizations. His depth of global
experience makes him well positioned to lead Phosphorex as we execute on our growth strategy to establish cGMP manufacturing for lipid nanoparticles.”

Jarlath Keating commented, “Dr. Wu has founded, grown, and led an exceptional drug delivery focused CDMO and team of premier scientists serving the pharma and biot vision i s to build upon this knowledge and experience, allowing Phosph mission as an end-to- e nd CDMO provider for lipid / polymer nanop other nanoparticle technologies. I am th rilled to join the organizatio point in the company’s evolution and look forward to se rving driving Phosphorex’s strategic growth plan.”

About Phosphorex
Phosphorex is a leading provider of drug delivery technologies and solutions. By harnessing the potential of microspheres and nanoparticles for drug delivery, Phosphorex offers tailored solutions and enabling technologies to optimize a drug’s relea ability , bioavailability, and deliverability, with the goal of a effects while reducin g adverse clinical outcomes. Phosphorex supports biotech companies through all phase s of their development, from p studies. Phosphorex’s mission is to help our partners so l ve complex pr successful drugs to help patients. Additional information about Phosphorex is available at www.phosphorex.com.

About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management
dedicated to growth-oriented investments in the healthcare sector. Wi MA and Am sterdam, Netherlands,
Ampersand leverages a unique blend of private equity and operatin and drive su p erior long-term
performance alongside its portfolio company management teams. Ampersand numerous market-leading
companies across each of the firm’s core healthcare sectors. Addition Ampers a nd is available
at www.ampersandcapital.com